Summary of Bright Minds Biosciences FY Conference Call Company Overview - **Company**: Bright Minds Biosciences (NasdaqCM:DRUG) - **Focus**: Development of novel serotonin-targeting drugs for various indications, particularly in epilepsy and Prader-Willi syndrome [2][26] Key Points on Lead Program (BMB-101) - **Indications**: Treatment of refractory absence seizures and Prader-Willi syndrome [2] - **Mechanism**: Targets 5-HT2C receptors without activity at 5-HT2A or 2B, representing a second or third generation of serotonin axis drugs [3] - **Formulation**: Developing a once-a-day oral tablet for absence seizures and a liquid formulation for patients with cognitive difficulties [4] - **Phase 1 Study Results**: - No serious adverse events reported - Good tolerability with transient issues at high doses [5] - 73% reduction in absence seizures and 63% reduction in DEE seizures observed in a small trial [6][15] Study Design and Patient Population - **Cohorts**: 24 subjects total, with 15 in the absence group and 9 in DEE, primarily Lennox-Gastaut syndrome [9] - **Refractory Nature**: Patients had failed multiple medications, with an average of 3.7 prior treatments for absence seizures and nearly 10 for DEE [9][21] - **Seizure Reduction**: Significant reductions in seizure frequency and duration, with a notable increase in REM sleep [17][18] Safety and Adverse Events - **Adverse Events**: No drug-related serious adverse events; common issues included fatigue, constipation, and headache [22][23] - **Safety Profile**: No new seizure types emerged, and the drug was well tolerated among participants [20] Regulatory and Market Outlook - **Regulatory Plans**: Starting global phase 3 studies for DEE and absence seizures; discussions ongoing with regulatory agencies [25][27] - **Market Potential**: Both indications are projected to be multi-billion dollar opportunities, with a focus on the treatment-refractory landscape [33] - **Competitive Landscape**: Current treatments like ethosuximide and valproate have limitations, creating a significant market opportunity for BMB-101 [34] Prader-Willi Syndrome (PWS) Opportunity - **Mechanism**: Aims to address hyperphagia and neurobehavioral symptoms associated with PWS by enhancing 5-HT2C receptor activity [36] - **Initial Results**: Patients in the seizure studies showed weight loss and reduced eating drive, indicating potential for similar outcomes in PWS [38] Future Developments - **Next Steps**: Initiating studies for BMB-105, with expected enrollment by next year and results anticipated in 2027 [40][41] - **Funding Utilization**: Recent financing will support the 5-HT2C program in epilepsy and the next readout for Prader-Willi syndrome [41]